- Language:
-
-
Innovation is in our DNA and we want to be part of your journey and advance your studies. CSI has successfully delivered oncology products all over the world. Treatments for cancer have been advancing at an accelerated pace in recent years. Offering significant improvements in clinical benefit as well as increased specificity through selection according to biomarkers or through engineered cell or gene therapies.
What do we offer?
Advances in cancer therapeutics
Over the past five years, 61 cancer drugs, each approved in one or more tumors, have impacted the treatment of 23 different cancer types. The rise of immuno-oncology since the first launches in 2014 has been largely centered on the PD-1 and PD-L1 mechanisms, so-called checkpoint inhibitors, which have broad efficacy across solid tumors and are used across 23 different tumor types.
The range of clinical benefits from this new group of medicines includes several with total remission rates above 50% and significant extensions of overall survival. As well as some with incremental survival benefits in tumors where those rates were already extremely high.
How do we do it?
Pipeline and prospects for clinical development
More than 700 cancer drugs are in late-stage development, up over 60% from a decade ago. Over one-third of trials are using biomarkers to stratify patients, pointing to even more personalised (and effective) cancer treatments in the future. At CSI, we design supply chains to minimise wastage and ensure sites have sufficient medication. We proactively manage your studies and deliver value.
First-generation antibodies - humanised inhibitors
Second generation antibodies - humanised inhibitors
info@csint.com
+44 (0)203 954 0517
